Keyword: Fujifilm Diosynth Biotechnologies
J&J CAR-T partner Legend aims for U.S. IPO. The FDA's not sure how many drugs and APIs come from China. Harbour teams with Mount Sinai on coronavirus.
Fujifilm Diosynth Biotechnologies has named a new CEO who takes over as the Japanese CDMO is in the midst of expanding.
Several influential institutions and biopharma companies have joined hands in developing COVID-19 therapies. Takeda's buying PvP for $330 million.
Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.
A new commercial-scale gene therapy manufacturing facility is being planned, but not by a biotech or a CDMO. This one will be built by a hospital.
Harvard and a host of players will build a $50 million clinical supply manufacturing facility near Boston for biotechs working on gene therapies.
Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.
A judge orders Allergan to turn over Botox production details; A U.S. senator urges the FDA to run surprise inspections; the FDA approves Daiichi's cancer drug.
CDMO Fujifilm Diosynth has acquired from Biogen a biologics production facility in Denmark with about 800 employees.
Fujifilm will buy biologics operations in Denmark from Biogen as the Japanese company continues to beef up its CDMO business.
